A new publication involving lanreotide was released on October 1, 2026. The paper, titled "Somatostatin analogues for ADPKD: ending the confusing story of mGFR and eGFR," appears in the journal Kidney International. The publication is listed under PubMed ID 42760021. It addresses somatostatin analogues, a drug class that includes lanreotide, in the context of autosomal dominant polycystic kidney disease, or ADPKD. The title references measured glomerular filtration rate (mGFR) and estimated glomerular filtration rate (eGFR) as topics discussed in the work. This brief reports only that the publication exists and the bibliographic details provided. No findings, outcomes, or data from the publication are included here. Readers interested in the substance of the discussion should consult the original article directly through the journal or PubMed listing. Lanreotide remains an approved compound, and this publication represents a new addition to the scientific literature concerning its use in somatostatin analogue research related to kidney disease. For additional background on lanreotide, see the compound overview linked with this brief.
Lanreotide Study Published in Kidney International on ADPKD
See the full lanreotide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42760021/